Edition:
United States

Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

2,049.00GBp
22 Feb 2017
Change (% chg)

2.00 (+0.10%)
Prev Close
2,047.00
Open
2,038.00
Day's High
2,058.00
Day's Low
2,038.00
Volume
49,547
Avg. Vol
760,922
52-wk High
2,703.00
52-wk Low
1,575.00

HIK.L

Chart for HIK.L

About

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe. The... (more)

Overall

Beta: 1.22
Market Cap(Mil.): £4,907.49
Shares Outstanding(Mil.): 239.97
Dividend: 8.40
Yield (%): --

Financials

  HIK.L Industry Sector
P/E (TTM): 30.43 28.39 29.32
EPS (TTM): 0.67 -- --
ROI: 6.46 13.54 13.03
ROE: 9.67 14.43 14.17

D.C. Circuit refuses to revive Takeda appeal to block rival gout drug

A federal appeals court has refused to revive Takeda Pharmaceutical Co and its hedge fund investor Elliott Associates' bid to block Hikma Pharmaceuticals PLC from selling its gout drug Mitigare.

Feb 13 2017

BRIEF-Hikma signs licensing deal with Orion for asthma product

* Signed an exclusive licensing and distribution agreement with Orion Corporation Of Finland, for its new Easyhaler combination product

Feb 13 2017

Takeda, Hikma clash again in D.C. Circuit over gout drug

Hikma Pharmaceuticals PLC is fighting back against a bid by Takeda Pharmaceutical Co and its hedge fund investor Elliott Associates to revive a case in a Washington, D.C. federal appeals court in order to block Hikma from selling its gout drug Mitigare.

Jan 25 2017

BRIEF-Hikma gets FDA nod for Sodium Oxybate oral solution

* Wholly owned US subsidiary, roxane has received an approval from US FDA for its Sodium Oxybate oral solution

Jan 18 2017

BRIEF-Hikma announces U.S. deal with Vectura for generic salmeterol development

* Announces agreement with Vectura for development of generic salmeterol for U.S. market Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

Nov 22 2016

BRIEF-Hikma Pharmaceuticals sees FY group revenue to grow by about 35 pct

* In US, good demand across a number of products and new product launches has more than offset increased competition for certain products

Nov 10 2016

BUZZ-Hikma: top Stoxx loser as HSBC cuts TP on DoJ market probe

** Hikma Pharma -c.7% in heavy vols, biggest loser on Stoxx & trading at lowest in 10 mnths as HSBC cuts TP to 1985p from 2525p

Nov 04 2016

BRIEF-Hikma says first-half revenue up 28 pct

* H1 group core operating profit of $176 mln, down 14 pct and down 3 pct in constant currency

Aug 24 2016

More From Around the Web

Earnings vs. Estimates